Adaptive Biotechnologies Plans Separation of Immune Medicine Platform, Eyes Strategic Options for Drug Discovery Business
核心洞察
Adaptive Biotechnologies announced plans to separate its immune medicine business from its cancer-testing unit, with a preferred path expected by the end of 2026.
The residual cancer-testing unit, anchored by the clonoSEQ (搜索) MRD test, has reached profitability with revenue growing from $103 million in 2023 to $212 million in 2025.
The immune medicine platform focuses on identifying therapeutic targets and accelerating precision medicine development through drug discovery applications.
Adaptive Biotechnologies announced on Monday that it plans to separate its immune medicine business from its residual cancer-testing unit, as the Seattle-based company reviews strategic options for its drug-discovery operations and sharpens its focus on diagnostics.
The company said it was reviewing options for the immune medicine business and expected to choose a preferred path by the end of 2026. The immune medicine platform helps conduct drug research by identifying therapeutic targets and accelerating the development of precision medicines.
"The immune medicine business might be better placed outside the company's diagnostics-focused model," Adaptive stated, signaling a strategic pivot toward its testing franchise.
Cancer-Testing Unit Reaches Profitability
The residual cancer-testing unit, which includes the clonoSEQ (搜索) test, has reached profitability and expanded insurance coverage, according to the company. ClonoSEQ is used to detect small traces of cancer that may remain after treatment — known as Minimal Residual Disease (MRD) — and is also utilized in drug-development studies.
The unit's revenue rose to $212 million in 2025, up from $103 million in 2023, reflecting significant commercial momentum for the MRD testing franchise.
Immune Medicine Platform and Drug Discovery
Adaptive's immune medicine platform combines proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data that decodes the adaptive immune system. The platform serves life sciences research, clinical diagnostics, and drug discovery applications, enabling partners to identify novel therapeutic targets and develop precision medicines.
The company, originally founded as Adaptive TCR Corporation in 2009 and renamed in 2011, has built its technology around an immunosequencing platform that leverages the adaptive immune system's biology to diagnose and monitor disease.
Strategic Review and Uncertainty
Adaptive cautioned that there is no assurance the review would result in a deal or any other outcome. The separation process is expected to unfold over the coming months as the company evaluates the best structure for both its drug-discovery and diagnostic businesses.